REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference taking place virtually from February 12 to 13, 2021 .
| ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference taking place virtually from February 12 to 13, 2021. The presentations will be as follows: Presentation Title: Subretinal Gene Therapy for Exudative AMD Presentation Title: Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas. Trademarks referenced herein are registered trademarks of REGENXBIO. Contacts: Investors: Media:
SOURCE REGENXBIO Inc. | ||
Company Codes: NASDAQ-NMS:RGNX |
View original content to download multimedia:
